論文・技術情報追加のお知らせ

1. Adverse events of Capmatinib: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.

カプマチニブに関連する79の副作用シグナルを特定

対象DB：FAERS

2. Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

MPAに関連する新たな副作用シグナルを特定

対象DB：FAERS

3. Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System.

薬剤性低フィブリノゲン血症に関連する薬物の特定

対象DB：FAERS

4. Associations of acute kidney injury with oral anticoagulants: a disproportionality analysis of the food and drug administration adverse event reporting system (FAERS) database.

OACs使用と急性腎障害(AKI)の関連性評価

対象DB：FAERS

5. Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA Adverse Events Reporting System (FAERS).

免疫・ターゲット治療薬の感染症リスク調査

対象DB：FAERS

6. Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study.

薬剤による黄斑浮腫のリスクを評価

対象DB：FAERS

7. An exploratory study evaluating the 20 medications most commonly associated with suicidal ideation and self-injurious behavior in the FAERS database.

抗うつ薬や抗てんかん薬が自殺念慮に関連

対象DB：FAERS

8. A real-world pharmacovigilance analysis for Demethylation drug: findings from the FDA adverse event reporting database.

アザシチジンとデシタビンの副作用、特に血液系や腫瘍関連で注意

対象DB：FAERS

9. Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review.

アレムツズマブによるTTP報告増加、注意必要

対象DB：FAERS

10. Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System.

免疫チェックポイント阻害薬の副作用は年齢別で異なる

対象DB：FAERS

11. Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.

薬剤による認知症リスクの特定と監視強化の必要性

対象DB：FAERS

12. Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database.

薬剤に起因する心不全と急性心不全のリスクを特定

対象DB：FAERS

13. Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database.

VEGFR-TKIは肝障害と関連し、パゾパニブが最も関連

対象DB：FAERS

14. Musculoskeletal adverse events associated with CDK4/6 inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database.

CDK4/6阻害剤で骨痛や骨壊死などの筋骨格毒性が報告

対象DB：FAERS

15. DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system.

DNAメチル化阻害剤で好中球減少症や血小板減少症が多い

対象DB：EudraVigilance,FAERS

16. Real-world safety evaluation of brivaracetam: insights from the US FDA adverse event reporting system.

ブリバラセタム使用で神経系や精神的副作用、妊娠・授乳中の注意

対象DB：FAERS

17. Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.

GLP-1アゴニストは糖尿病網膜症と関連

対象DB：FAERS

18. Post-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS).

ピマバンセリンで新たな副作用信号、性別差あり

対象DB：FAERS

19. Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system.

SSRI使用で体重増加や代謝異常のリスク増加、薬剤ごとに違い

対象DB：FAERS

20. Antibiotics-induced pulmonary embolism: A disproportionality analysis in Food and Drug Administration database of Adverse Event Reporting System using data mining algorithms.

ミノサイクリン、クロラムフェニコール、モキシフロキサシンで肺塞栓症のリスク増加

対象DB：FAERS

21. Post-Marketing Safety of Temozolomide: A Pharmacovigilance Study Based on the Food and Drug Administration Adverse Event Reporting System.

テモゾロミドで新たな副作用、特に骨髄抑制や肺炎などが確認

対象DB：FAERS

22. Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS).

カナキヌマブ使用で感染症の重篤な副作用が多発

対象DB：FAERS

23. A Comprehensive 10-Year Nationwide Pharmacovigilance Surveillance on Antibacterial Agents in Korea: Data Mining for Signal Detection of Trends and Seriousness of Adverse Events.

抗菌薬使用で心血管や尿路障害が重篤な副作用に関連

対象DB：FAERS,KAERS

24. Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders.

VEGFR-TKI使用で味覚・嗅覚障害のリスク増加、特にカボザンチニブ

対象DB：FAERS

25. Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system.

アバプリチニブ使用で神経精神的副作用のリスク増加

対象DB：FAERS

26. Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese adverse drug event report database: a retrospective pharmacovigilance study.

抗コリン薬の総負荷が副作用リスク評価に有用

対象DB：JADER

27. BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study.

BRAF治療の再挑戦で約40%が初回副作用再発

対象DB：VigiBase

28. Impact of COVID-19 on resuscitation after hospital arrival for patients with out-of-hospital cardiac arrest: An interrupted time series analysis.

COVID-19パンデミックでOHCA患者の気管挿管が減少

対象DB：DPC

29. Prevalence and clinical impact of disseminated intravascular coagulation in acute aortic dissection: a nationwide cohort study.

急性大動脈解離患者におけるDICは院内死亡率を増加させる

対象DB：JMDC

30. Impact of potentially inappropriate medications on emergency ambulance admissions in geriatric patients after discharge.

高齢者のPIM使用が救急搬送リスクに関連

対象DB：JMDC

31. Actual Use of Budesonide Enteric-Coated Capsules for Crohn's Disease in Japan: Analysis of Health Insurance Big Data.

長期ブデソニド使用で副作用増加なし、モニタリング不足

対象DB：JMDC

32. Antiretroviral therapies and status of people living with HIV in Japan: An update from hospital survey and national database.

日本のHIV治療は高い治療継続率とウイルス抑制率を達成

対象DB：NDB

33. Intravenous immunoglobulin for mortality and inflammatory status in patients with sepsis: a retrospective database study.

IVIGは敗血症の死亡率を低下させる可能性あり

対象DB：MDV

34. Hearing loss and risk of major osteoporotic fracture: a population-based cohort study in the United Kingdom.

難聴者は骨折リスクが8-10%高い

対象DB：CPRD

35. Continuity and locum use for acute consultations: observational study of subsequent workload.

継続的なGP診療は医療負担を軽減

対象DB：CPRD

36. Monitoring for 5-aminosalicylate nephrotoxicity in adults with inflammatory bowel disease: prognostic model development and validation using data from the Clinical Practice Research Datalink.

5-ASA腎毒性のリスク予測モデルを開発・検証

対象DB：CPRD

37. Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study.

IPF患者のPPI・ICS使用は肺炎入院リスク増加と関連

対象DB：CPRD

38. Epidemiology of gender dysphoria and gender incongruence in children and young people attending primary care practices in England: retrospective cohort study.

2011-2021年で性別違和の診断が増加し、特に女性で顕著

対象DB：CPRD

39. Benzodiazepine-Free Cardiac Anesthesia for Reduction of Postoperative Delirium: A Cluster Randomized Crossover Trial.

心臓手術時のベンゾジアゼピン制限はせん妄を減少せず

対象DB：CVAR

40. Comparison of the incidence of proteinuria and changes in eGFR among febuxostat and topiroxostat users.

トピロキソスタットはフェブキソスタットより蛋白尿リスク低下

対象DB：DeSC

41. The family in preventing delirium in the intensive care unit: Scoping review.

家族介入がICUせん妄予防に有効であり、訪問延長や活動支援が効果的

対象DB：DeSC